- Correspondence
- Open access
- Published:
PTK2 is a potential biomarker and therapeutic target for EGFR- or TLRs-induced lung cancer progression via the regulation of the cross-talk between EGFR- and TLRs-mediated signals
Biomarker Research volumeĀ 12, ArticleĀ number:Ā 52 (2024)
Abstract
Protein tyrosine kinase 2 (PTK2), epidermal growth factor receptor (EGFR), and toll-like receptor (TLRs) are amplified in non-small cell lung cancer (NSCLC). However, the functional and clinical associations between them have not been elucidated yet in NSCLC. By using microarray data of non-small cell lung cancer (NSCLC) tumor tissues and matched normal tissues of 42 NSCLC patients, the genetic and clinical associations between PTK2, EGFR, and TLRs were analyzed in NSCLC patients. To verify the functional association, we generated PTK2-knockout (PTK2-KO) lung cancer cells by using CRISPR-Cas9 gene editing method, and performed in vitro cancer progression assay, including 3D tumor spheroid assay, and in vivo xenografted NSG (NOD/SCID/IL-2RĪ³null) mouse assay. Finally, therapeutic effects targeted to PTK2 in lung cancer in response to EGF and TLR agonists were verified by using its inhibitor (Defactinib). In summary, we identified that up-regulated PTK2 might be a reliable marker for EGFR- or TLRs-induced lung cancer progression in NSCLC patients via the regulation of the cross-talk between EGFR- and TLRs-mediated signaling. This study provides a theoretical basis for the therapeutic intervention of PTK2 targeting EGFR- or TLRs-induced lung cancer progression.
To the editor
Accumulating evidence has demonstrated that the expression of PTK2, EGFR, or TLRs is associated with lung cancer [1,2,3]. Nevertheless, the functional and clinical associations between them in the regulation of lung cancer progression remain uncertain.
This study, as illustrated in Fig. S1, was designed to address the functional association of PTK2, EGFR, and TLRs in 42 NSCLC patients. We utilized the differential magnitude (ĪMag) analysis approach to stratify 42 NSCLC patients based on the expression levels of each gene in lung tumor tissues (nā=ā42) compared to matched lung normal tissues (nā=ā42). Subsequently, we calculated the survival rate based on the gene expression profile and patientsā clinical status. In the first association study between PTK2up NSCLC patients (Death, nā=ā19) and PTK2down NSCLC patients (Alive, nā=ā11), we found that gene sets related to cancer modules and cancer progression were highly enriched in PTK2up NSCLC patients (Death, nā=ā19) (Fig. 1A; Table S1; Fig. S2A-Q; Fig. 1B; Fig. S3A-I), indicating that PTK2 expression is critically associated with cancer progression and poor survival rate in NSCLC patients (Fig. 1C, D). Importantly, gene sets related to cell cycle and NSCLC were significantly enriched in PTK2up NSCLC patients (Death, nā=ā19) (Fig. 1E). To verify the PTK2 expression in lung cancer progression, PTK2-knockout (PTK2-KO) human lung cancer cells were generated by using CRISPR-Cas9 gene editing method (Fig. 1F, G; Fig. S4) [4,5,6,7,8,9]. The ability of cell proliferation, migration, and colony formation was significantly decreased in PTK2-KO A549 and PTK2-KO H1299 cells (Fig. S5A-J) [5,6,7,8,9]. Furthermore, 3D tumor spheroid formation assay revealed the marked attenuation of tumor spheroids in PTK2-KO A549 and PTK2-KO H1299 cells as compared to those of Ctrl A549 and Ctrl H1299 cells, respectively (Fig. 1H, I; Fig. S6A, B) [6, 10]. Notably, NSG mice xenografted with the PTK2-KO A549 cells showed a marked decrease in tumor growth (Fig. 1J, K) and metastasis into the lung tissues (Fig. 1L) as compared to NSG mice xenografted with the Ctrl A549 cells [11], strongly supporting the results of gene sets in PTK2up NSCLC patients (Death, nā=ā19) vs. PTK2down NSCLC patients (Alive, nā=ā11). Importantly, gene sets related to EGFR-associated pathways were enriched in PTK2up NSCLC patients (Death, nā=ā19) (Fig. 1M; Fig. S7A-C). Therefore, we tried to assess the association between PTK2 and EGFR in NSCLC patients (2nd association study indicated in Fig. S1; Table S2; Fig. 1N). Patient survival was remarkably decreased in EGFRupPTK2up NSCLC patients (Figs. 1O and 29% vs. 86%). GSEA revealed that gene sets related to cancer modules and cancer progression were highly enriched in PTK2upEGFRup NSCLC patients (nā=ā7) vs. PTK2downEGFRdown NSCLC patients (nā=ā7) (Table S3; Fig. S8A-T; Fig. S9A-I). Moreover, gene sets related to FAK, EGFR-associated, and TOLL-associated pathways were highly enriched in PTK2upEGFRup NSCLC patients (nā=ā7) (Fig. S10A-L), supposing that PTK2 may be functionally involved in the EGFR- and TLR-mediated signaling. To verify the functional association, we performed a biochemical assay. Interestingly, PTK2 interacted with EGFR and enhanced the activation of EGFR (Fig. 2A-C). Moreover, PTK2 interacted with TLR-mediated signaling molecules, such as TRAF6, IRAK1, and TAK1, and induced the activation of these proteins in responses to Pam3CSK4 (a TLR1/2 agonist) and FSL-1 (a TLR2/6 agonist) (Fig. S11A-J; Fig. 2D, E), leading to the activation of NF-ĪŗB in a PTK2-dependent manner (Fig. 2F, PTK2-KO A549 vs. Ctrl A549), suggesting that PTK2 positively regulates EGFR- and TLRs-mediated signaling for the activation of NF-ĪŗB (depicted in Fig. S11K).
Given the above results, we further tried to assess the association between them, PTK2, EGFR, TLR1, TLR2, and TLR6, in NSCLC patients (3rd association study indicated in Fig. S1; Table S4; Fig. S12A). Importantly, GSEA revealed that gene sets related to cancer modules and cancer progression were highly enriched in TLR1upTLR6upTLR2upPTK2upEGFRup NSCLC patients (nā=ā5) vs. TLR1downTLR6downTLR2downPTK2downEGFRdown NSCLC patients (nā=ā4) (Fig. S12B-N; Fig. S13A-L). Furthermore, gene sets related to EGFR-associated pathways were significantly enriched in TLR1upTLR6upTLR2upPTK2upEGFRup NSCLC patients (nā=ā5) (Fig. S14A-F). To verify the functional association between them, PTK2-KO A549 and PTK2-KO H1299 cells were treated with vehicle, Pam3CSK4, FSL-1, EGF, Pam3CSK4 plus EGF, FSL-1 plus EGF, and cancer progression assay and 3D tumor spheroid formation assay were performed. Interestingly, the ability of cell proliferation, migration, colony formation, and 3D spheroid formation were significantly attenuated in PTK2-KO A549 and PTK2-KO H1299 cells treated with vehicle, Pam3CSK4, FSL-1, EGF, Pam3CSK4 plus EGF, FSL-1 plus EGF, as compared to those of Ctrl A549 and Ctrl H1299 cells (Fig. S15A-H; Fig. S16A, B; Fig. S17A-H; Fig. S18A-F; Fig. S19; Fig. 2G, H), suggesting that PTK2 is functionally implicated in EGFR- and TLRs-mediated cancer progression. Having shown these results, we finally assessed whether PTK2 is a potential therapeutic target for the lung cancer progression induced by EGFR and TLRs. To do that, we used Defactinib, an inhibitor PTK2 [12], and performed a 3D tumor spheroid formation assay after the determination of IC50 in A549 and H1299 lung cancer cells (Fig. S20A, B; Fig. S21A, B). Notably, Defactinib effectively inhibited the 3D tumor spheroid formation of wild type A549 and H1299 cells in response to Pam3CSK4, FSL-1, LPS, EGF, Pam3CSK4 plus EGF, FSL-1 plus EGF, or LPS plus EGF as compared to those of the treatment of vehicle (Fig. S22A-C; Fig. S23A; Fig. 2I, J).
In summary, our results for the first time demonstrate that PTK2 expression is functionally associated with EGFR and TLRs in lung cancer progression (Fig. S23B), and the inhibition of PTK2 activity leads to the attenuation of lung cancer progression induced by EGF, TLRs, and EGF plus TLRs. We strongly believe that the current work can be a milestone in the field of precision cancer medicine developing valuable biomarkers targeted to EGFR or TLRs in lung cancer therapy.
Data availability
All data related to this article are shown or available upon request from the corresponding authors.
Abbreviations
- PTK2:
-
Protein tyrosine kinase 2
- NSCLC:
-
Non-small cell lung cancer
- EGFR:
-
Epidermal growth factor receptor
- TLR:
-
Toll-like receptor
- CRISPR-Cas9:
-
Clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9
- NSG:
-
NOD scid gamma mouse
- ĪMag:
-
Differential magnitude
- GSEA:
-
Gene set enrichment assay
- NES:
-
Normalized enrichment score
- FDR:
-
False discovery rate
- NF-ĪŗB:
-
Nuclear factor kappa-light-chain-enhancer of activated B cells
- IRAK:
-
Interleukin-1 receptor-associated kinase
- TRAF6:
-
Tumor necrosis factor receptor associated factor 6
- TAK1:
-
Transforming growth factor-Ī²-activated kinase 1
References
Tong X, et al. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer. Respir Res. 2019;20(1):270.
Bethune G, et al. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2010;2(1):48ā51.
Gu J, et al. Roles of toll-like receptors: from inflammation to lung cancer progression. Biomed Rep. 2018;8(2):126ā32.
Cong L, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819ā23.
Kim MJ, et al. The SARS-CoV-2 spike protein induces lung cancer migration and invasion in a TLR2-dependent manner. Cancer Commun (Lond). 2024;44(2):273ā7.
Shin JH, et al. CXCR5 and TLR4 signals synergistically enhance non-small cell lung cancer progression. Clin Transl Med. 2024;14(1):e1547.
Kim JY, et al. Ī²-arrestin 2 negatively regulates lung cancer progression by inhibiting the TRAF6 signaling axis for NF-ĪŗB activation and autophagy induced by TLR3 and TLR4. Cell Death Dis. 2023;14(7):422.
Kim JY, et al. Stratifin (SFN) regulates lung cancer progression via nucleating the Vps34-BECN1-TRAF6 complex for autophagy induction. Clin Transl Med. 2022;12(6):e896.
Kim MJ, et al. CRBN is downregulated in lung cancer and negatively regulates TLR2, 4 and 7 stimulation in lung cancer cells. Clin Transl Med. 2022;12(9):e1050.
Vega VF, et al. Protocol for 3D screening of lung cancer spheroids using natural products. SLAS Discov. 2023;28(2):20ā8.
Kim MJ, et al. USP8 regulates liver cancer progression via the inhibition of TRAF6-mediated signal for NF-ĪŗB activation and autophagy induction by TLR4. Transl Oncol. 2022;15(1):101250.
Wang-Gillam A, et al. Defactinib, Pembrolizumab, and Gemcitabine in patients with Advanced Treatment Refractory Pancreatic Cancer: a phase I dose escalation and expansion study. Clin Cancer Res. 2022;28(24):5254ā62.
Acknowledgements
We would like to thank Hyehwa Forum members for their helpful discussion.
Funding
This work was supported by the National Research Foundation of Korea Grants funded by the Korean Government (2023R1A2C1003762, 2021R1A2C1094478, and RS-2023-00217189).
Author information
Authors and Affiliations
Contributions
Conceptualization, Eunyoung Chun and Ki-Young Lee; Investigation, Ji Young Kim, Ji Hye Shin, Mi-Jeong Kim, Bongkum Choi, Yeeun Kang, Jimin Choi, Seo Hyun Kim, Dohee Kwan; Data curation, Bongkum Choi, Mi-Jeong Kim, Eunyoung Chun and Ki-Young Lee; Formal analysis, Ji Young Kim, Ji Hye Shin, Mi-Jeong Kim, Bongkum Choi, Dohee Kwan; Funding acquisition, Eunyoung Chun and Ki-Young Lee; Methodology, Ji Young Kim, Ji Hye Shin, Mi-Jeong Kim, Bongkum Choi, Yeeun Kang, Jimin Choi, Seo Hyun Kim, Dohee Kwan and Duk-Hwan Kim; Project administration, Eunyoung Chun and Ki-Young Lee; Software, Ji Young Kim, Ji Hye Shin, Mi-Jeong Kim, Bongkum Choi, Dohee Kwan, Eunyoung Chun and Ki-Young Lee; Supervision, Eunyoung Chun and Ki-Young Lee; Visualization, Ji Young Kim, Ji Hye Shin, Mi-Jeong Kim, Eunyoung Chun and Ki-Young Lee ; Writing ā original draft, Eunyoung Chun and Ki-Young Lee; Writing ā review & editing, Eunyoung Chun and Ki-Young Lee.
Corresponding authors
Ethics declarations
Ethics approval and consent to participate
Tumor and matched normal tissues from 42 patients with primary NSCLC were obtained in accordance with the ethical principles stated in the Declaration of Helsinki. This study was approved by the Institutional Review Board of Samsung Medical Center (IRB#: 2010-07-204). We obtained written informed consent from each patient prior to surgery for using their pathological specimens for research use. All animal experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of the Bioanalysis Center Animal Facility (IACUC #: 23-10-01), GenNBio Inc.
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Additional information
Publisherās Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the articleās Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the articleās Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Kim, J.Y., Shin, J.H., Kim, MJ. et al. PTK2 is a potential biomarker and therapeutic target for EGFR- or TLRs-induced lung cancer progression via the regulation of the cross-talk between EGFR- and TLRs-mediated signals. Biomark Res 12, 52 (2024). https://doi.org/10.1186/s40364-024-00604-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s40364-024-00604-x